Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: Long-term results

Urologia Internationalis

Volumn 61, Issue 4, 1998, Pages 220-226

  Hurle, R ^a,b   Manzetti, A ^a   Losa, A ^a   Micheli, E ^a   Ranieri, A ^a   Chinaglia, D ^a   Lembo, A ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

Author keywords

Bladder neoplasms; Carcinoma; Drug therapy; Mitomycin C; Transitional cell

Indexed keywords

MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMICAL CYSTITIS; CYSTITIS; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HEMATURIA; HIGH RISK POPULATION; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCINS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 0032459240     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030333     Document Type: Article

References (32)

1. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR, for the National Bladder Cancer Collaborative Group A: Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083-1086.
2. Lamm DL, Griffith G, Pettit LL, Nseyo UO: Current perspectives on diagnosis and treatment of superficial bladder cancer. Urology 1992;39:301-308.
3. Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH, for the National Bladder Cancer Collaborative Group A: Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 1983;130:677-780.
4. Kurt KH, Schroder FH, Tunn U, Ay R, Pavone-Macaluso M, Debruyne F, De Pauw M, Dalesio O, Ten Kate F, the members of the European Organization for Research and Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group: Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: Preliminary results of a European organization for research on treatment of cancer randomized trial comparing doxorubicin, hydrochloride, ethoglucid and transurethral resection alone. J Urol 1984;132:258-262.
5. Melekos MD, Dauaher H, Fokaefs E, Barbalias G: Intravesical instillation of 4-epi-doxorubicin (epirubicin) in the prophylcactic treatment of superficial bladder cancer: Results of a controlled, prospective study. J Urol 1992;147: 371-275.
6. Tolley DA, Parmar MKB, Grigor KM, Lallemand G, the Medical Research Council Superficial Bladder Cancer Working Party: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer. A further report with 7 years of follow up. J Urol 1996;155:1233-1238.
7. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153: 1444-1450.
8. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, Van Der Meijden A, Parmar MKB, Bijnens L, for the Members of the European Organization for Research and Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer: A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaTl bladder cancer. J Urol 1996;156:1934-1941.
9. Huland H, Otto U, Droese M, Kloppel G: Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J Urol 1984;132:27-29.
10. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A: Low dose Pasteur bacillus Calmette-Guérin regimen in stage Tl, grade 3 bladder cancer therapy. J Urol 1996;156:1602-1605.
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-462.
12. Lee ET: Statistical Methods for Survival Data Analysis. Belmont, Lifetime Learning, 1980, pp 19-26, 109-112.
13. Cox DR: Regression models and life-tables. J R Stat Soc Ser B 1972;34:187-192.
14. Soloway MS: Editorial: Intravesical therapy for bladder cancer. J Urol 1994;152:379-381.
15. Rubben H, Graf-Dobberstein C, Ostwald R, Stauffemberg A, Jaeger N, Duetz FJ, Steffens L, Giani G: Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer: Mitomycin C vs. BCG Connaught vs. TUR alone; in deKernion JB, Mazema E (eds): Immunotherapy of Urological Tumours. New York, Churchill Livingstone, 1990, pp 27-36.
16. Shida K: Treatment of the bladder cancer with instillation of mitomycin C (first report). Jpn J Clin Urol 1967;21:1075-1077.
17. van der Meijden APM, DeBruyne FMJ: Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: Short-term course or maintenance therapy. Urology 1988;31(suppl):26-29.
18. Soloway MS: Selecting initial therapy for bladder cancer. Cancer 1987;60:502-513.
19. Heney NM, Nocks BN, Daly JJ, Prout GR Jr, Newall JB, Griffin PP, Perrone TL, Szyfelbein WA: Ta and Tl bladder cancer: Location, recurrence and progression. Br J Urol 1982;54: 152-157.
20. van der Werf-Messing B, Hop WCJ: Carcinoma of the urinary bladder (category TlNxMo) treated either by radium implant or by transurethral resection only. Int J Radiat Oncol Biol Phys 1981;7:299-301.
21. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD: Superficial bladder tumors (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection. J Urol 1986;135:920-922.
22. Malmstrom P, Busch C, Norlen BJ: Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol 1987;21:185-195.
23. Lundholm C, Norlen BJ, Ekman P, Jahnson S, Lagerkvist M, Lindborg T, Olsson JO, Tveter K, Wijkstrom H, Westberg R, Malmstrom P: A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1996; 156:372-376.
24. Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegoraro C, Selvaggi F, Salvia G, Comeri G, Bono A, Borella T, Giuliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin Oncol 1994;12: 7-13.
25. Vegt PDJ, Witjes JA, Witjes WPJ, Doesburg WH, Debruyne FMJ, van der Meijden APM: A randomized study of intravesical mitomycin C, bacillus Calmette-Guérin Rivm treatment in pTa-pTl papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995;153:929-933.
26. Minervini R, Felipetto R, Viganò L, Pampaloni S, Fiorentini L: Recurrence and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up. Urol Int 1996;56:234-237.
27. Maier U, Hobarth K: Long-term observation after intravesical metaphilaxis with mitomycin C in patients with superficial bladder tumors. Urology 1991;37:481-482.
28. Milani C, Bassi P, Meneghini A, Garbeglio A, Zattoni F, Piazza N, Maruzzi D, Drago-Ferrante GL, Pagano F: Mitomycin C in multiple superficial bladder tumoris: short-term therapy, long-term results. Urol Int 1992;48:154-156.
29. Kim HH, Lee C: Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J Urol 1989;141: 1337-1339.
30. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Withmore WF Jr, Oettgen HF: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-years follow-up of a prospective randomized trial. J Clin Oncol 1995;13:1404-1408.
31. Akaza H, Koiso K, Kotake T, Matsumura Y, Ysaka S, Machida T, Obata K, Ohashi Y, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Kagawa S, Niijima T, the Japanese Urological Cancer Research Group for Adriamycin: Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: Experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 1992;30(suppl):15-20.
32. Jaske G, Loidl W, Seeber G, Hofstädter F: Stage Tl, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 1987;137:39-43.